Fresenius SE & Co. KGaA · XETR:FRE

Fresenius SE & Co. KGaA — Merger or Acquisition (September 2016)

16 slides from Fresenius SE & Co. KGaA's merger presentation, Sep 6, 2016

  1. Slide 1: Acquisition of Quirónsalud

    Acquisition of Quirónsalud Bad Homburg, 6 September 2016

  2. Slide 2: Safe Harbor Statement

    Safe Harbor Statement This presentation contains forward-looking statements that are subject to various risks and uncertainties. Future results could differ materially from those described in these forward-looking statements due to certain factors, e.g. changes in business, economic and competitive

  3. Slide 3: Transaction Highlights

    Transaction Highlights Market leader in size and quality with excellent growth prospects Strong management team with proven track record and ongoing commitment to Fresenius Combination forms powerful platform for knowledge & best practice transfer Substantial cost and growth synergies Highly accreti

  4. Slide 4: Excellent Reputation in the Spanish Hospital Market

    Excellent Reputation in the Spanish Hospital Market Market leader Quality leader Nationwide footprint Economies of scale Strong revenue Payor diversity / growth potential strong revenue base Acquisition of Quirónsalud, Fresenius SE & Co. KGaA, Investor Relations, © Copyright, 6 September 2016 4

  5. Slide 5: Quirónsalud – Corporate History

    Quirónsalud – Corporate History Further acquisitions of hospitals Madrid San Sebastian Palma d. M. Pontevedra Sevilla • #1 private hospital group in Spain • €926 m revenue in 2014 • 70% of revenue from NHS New business segment “ORP“ • #2 private hospital group in Spain • €823 m revenue in 2014 • 95%

  6. Slide 6: Hospital Network With Clear Focus on Large Metropolitan Areas

    Hospital Network With Clear Focus on Large Metropolitan Areas Bilbao 43 hospitals, 39 outpatient centers ~300 ORP centers Saragossa ~€2.5bn Sales (2016e) Barcelona Madrid €460 – 480m EBITDA (2016e) 6,600 beds and Valencia 35,000 staff Palma 9.4m outpatient admissions p.a. Sevilla 320,000 inpatient a

  7. Slide 7: Spanish Health Care Market – Key Facts

    Spanish Health Care Market – Key Facts Total health care expenditure Hospital discharges (% of GDP) (per 1,000 inhabitants) 250 11.1% 11.0% 9.8% 9.0% 8.9% 170 130 100 90 Germany France UK Spain Portugal Germany France UK Spain Portugal Average length of stay Hospital beds (days) (per 1,000 inhabitan

  8. Slide 8: Private Health Care System in Spain

    Private Health Care System in Spain Public insurance Public insurance NHS tax-funded funded by social security contributions Private full coverage insurance Private full coverage Complement- HIC additional to insurance instead of ary private public insurance public insurance insurance Employees with

  9. Slide 9: Broad Revenue Base of Quirónsalud Driven by Diversified Payor and Patient Split

    Broad Revenue Base of Quirónsalud Driven by Diversified Payor and Patient Split Private - HIC Public – NHS (PPPs) Other • Agreements with all relevant HICs • 5 long-term concession hospitals 4 in Madrid and 1 in Barcelona • Full reimbursement of all medical 3% services • Remuneration per capita with

  10. Slide 10: Structural Growth Drivers

    Structural Growth Drivers Health care expenditure per capita in Spain below EU average Close dovetailing of inpatient and outpatient care Public – NHS (PPPs) Expansion of existing facilities Greenfield projects Acquisition of private hospitals Acquisition of Quirónsalud, Fresenius SE & Co. KGaA, Inv

  11. Slide 11: Financial Outlook

    Financial Outlook Sales EBITDA €m €m ~2,700 520 ‒ 550 460 ‒ 480 ~2,500 406 2,372 2015 2016e 2017e 2015 2016e 2017e Acquisition of Quirónsalud, Fresenius SE & Co. KGaA, Investor Relations, © Copyright, 6 September 2016 11

  12. Slide 12: Financially Sound Acquisition (I)

    Financially Sound Acquisition (I) Depreciation • ~4% of sales in FY16; good proxy for following years Amortization • Initially ~€150 m1 p.a. Cost of Debt • ~2.0% Tax rate • 25% EAT bef. amortization • 2017e >€200 m CAPEX • ~4% of sales in FY16; good proxy for following years 1 Preliminary, before fi

  13. Slide 13: Financially Sound Acquisition (II)

    Financially Sound Acquisition (II) Total consideration • €5.76 bn (on a cash and debt-free basis) • Approx. 10.8x1 EBITDA 2017e Financing • Issuance of ~6.1 m shares valued at €400 m to Victor Madera • Balance of the purchase price debt-financed Net debt/EBITDA • 2016 pro forma ~3.1x • 2017e back wi

  14. Slide 14: Integration by Interaction

    Integration by Interaction Processes Services Procurement Results Length of stay Service App Quality Peer & Germans in Management Spain reviews Short waiting periods Mid-term incremental pre-tax synergies of approx. €50 m p.a. 14 Acquisition of Quirónsalud, Fresenius SE & Co. KGaA, Investor Relation

  15. Slide 15: Share Information

    Share Information Share key facts Number of shares1 546,652,116 WKN / ISIN 578560 / DE0005785604 Ticker symbol FRE Bloomberg symbol FRE GR Reuters symbol FREG.de ADR key facts Ratio 4 ADRs = 1 ordinary share ADR CUSIP / ISIN 35804M105 / US35804M1053 Ticker symbol FSNUY Exchange OTCQX International P

  16. Slide 16: Financial Calendar / Contact

    Financial Calendar / Contact Financial Calendar 2016 27.10.2016 Report on 3rd quarter 2016 Please note that these dates could be subject to change. Contact Investor Relations Fresenius SE & Co. KGaA phone: +49 6172 608-2485 e-mail: [email protected] For further information and current news: www.f

Fresenius SE & Co. KGaA — Merger or Acquisition (September 2016) on 6ix